Board of Directors

Dr Steven Powell
Chairman

Dr Powell has over thirty years of operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia. He has held six CEO roles, three in public companies. His current roles include CEO of French oncology company, Ribonexus, and Chair of Norwegian oncology development company, Hemispherian. In 2003, he joined Gilde Healthcare, a pan-European life sciences investment fund, as a partner and remained an adviser to the fund until 2016.

 

Dr Matthew Stork
Chief Executive Officer

Dr Stork has twenty-five years’ experience of managing companies in the med tech sector and expertise in AI, IT, diagnostics, medical equipment, and pharmaceuticals. He has a degree in pharmacy from the University of Bath, a PhD in Artificial Intelligence in Medicine from King’s College London, and an MBA from London Business School. Before becoming CEO of Cambridge Cognition in 2019, he held managing director and divisional leadership roles within GE Healthcare Digital, InHealth Group, ArjoHuntleigh, Canon Medical Systems (formerly Toshiba) and Smith & Nephew.

 

Stephen Symonds
Chief Financial Officer

Mr Symonds is an experienced finance professional and was until recently the Chief Financial Officer of Envigo, a private equity backed provider of pre-clinical services for the pharmaceutical industry, where he spent eight years.  Prior to that, he spent a decade with KPMG, working on a wide-ranging portfolio of clients.  Earlier in his career, he built a broad experience in a variety of small to medium-size accounting companies and as the finance lead in a family-owned business.

 

Debra Leeves
Non-Executive Director

Ms Leeves is currently CEO of Vertual, the leading provider of virtual and augmented reality training simulation systems in radiotherapy. She has over 25 years of experience in the medical technology and biotechnology industries, and has previously been COO of Beckley Canopy Therapeutics, CEO of Physeon and also held senior roles with companies such as Rex Bionics, Avita Medical, Merck, GlaxoSmithKline, GE Healthcare and Pfizer.

 

Richard Bungay
Non-Executive Director​

Mr. Bungay has over 25 years' experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CEO and CFO of both public and private companies, with a particular focus on financing, investor relations and corporate development. Mr Bungay is currently CEO of Imophoron Limited, a private company developing treatments for infectious diseases. Prior to this, Mr Bungay was CFO then CEO of AIM-listed Diurnal Group plc, where he led the sale of the company to Neurocrine Biosciences. Mr Bungay qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University.